News|Articles|November 16, 2026

FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis

Fact checked by: Ashley Gallagher, MA
Listen
0:00 / 0:00

Key Takeaways

  • Gefurulimab targets complement C5 and also binds serum albumin to extend half-life, enabling weekly subcutaneous dosing with a self-administered autoinjector in AChR-positive gMG.
  • PREVAIL demonstrated superior functional benefit at week 26, with MG-ADL least-squares mean change −4.2 vs −2.6 (difference −1.6; P<.001) and higher ≥3-point responder rates.
SHOW MORE

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

The FDA approved gefurulimab (Klygefa; AstraZeneca/Alexion) to treat adults with generalized myasthenia gravis (gMG) who are antiacetylcholine receptor (AChR) antibody-positive.1

The decision makes gefurulimab the first and only dual-binding nanobody C5 inhibitor for this population and offers once weekly subcutaneous self-administration via an autoinjector. The treatment works by binding to the C5 protein in the complement cascade, which, when activated in an uncontrolled manner, can trigger an immune response that damages healthy cells. Gefurulimab also binds to serum albumin, extending its half-life and enabling once-weekly dosing.

“We are proud to have discovered and developed this novel dual-binding nanobody and look forward to soon delivering this pioneering innovation to adults with gMG in the US, offering the established efficacy and safety of C5 inhibition with added convenience,” Marc Dunoyer, CEO of Alexion, said in a news release.

Phase 3 PREVAIL Trial Supports Gefurulimab Approval

Today’s approval was based on positive results from the phase 3 PREVAIL trial (NCT05556096), a randomized, double-blind, placebo-controlled, parallel, multicenter study evaluating the safety and efficacy of gefurulimab in adults with gMG.

The trial enrolled 260 patients from 20 countries, with participants required to have a confirmed MG diagnosis at least 3 months before the screening visit. Eligible patients also had a positive serological test for autoantibodies against AChR, as well as Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.

Patients were randomized 1:1 to receive gefurulimab or placebo for 26 weeks in the randomized treatment period. They received a single weight-based loading dose on day 1, followed by regular weight-based maintenance dosing beginning on day 8 and once weekly thereafter.

Change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score, the trial’s primary end point that measured patients’ abilities to perform daily activities, was assessed at week 26, along with multiple secondary end points evaluating improvement in disease-related measures. Patients who completed the randomized treatment period were eligible to enter an ongoing open-label extension to evaluate gefurulimab’s safety and efficacy further.

Recently published in JAMA Neurology, the trial found that adults with gMG who tested positive for AChR antibodies showed greater gains in daily functioning with self-injected gefurulimab once a week than with placebo.2 Specifically, at week 26, the least-squares mean MG-ADL score decreased by 4.2 points with gefurulimab vs 2.6 points with placebo (between-group difference, −1.6; 95% CI, −2.4 to −0.8; P < .001). An MG-ADL reduction of at least 3 points was seen in 82 of 125 (65.6%) in the gefurulimab arm and 63 of 121 (52.1%) in the placebo arm (OR, 1.74; 95% CI, 1.03-2.93; P = .04).

Regarding the trial’s key secondary end point, Quantitative Myasthenia Gravis (QMG) scores dropped 4.5 points with gefurulimab vs 2.4 points with placebo (difference, −2.1; 95% CI, −3.1 to −1.1; P < .001). A total of 58 of 124 patients (46.8%) had a QMG reduction of at least 5 points in the gefurulimab arm and 33 of 118 (28.0%) in the placebo arm (OR, 2.56; 95% CI, 1.42-4.62; P = .002). In addition, Myasthenia Gravis Composite scores improved by 7.8 points with gefurulimab and 4.7 with placebo (difference, −3.1; 95% CI, −4.4 to −1.7; P < .001).

Long-Term Data Still Needed

Safety findings were comparable between arms, with similar adverse event (AE) rates. Specifically, 99 patients (75.6%) receiving gefurulimab reported any AE, as did 104 (80.6%) receiving placebo; most AEs were mild or moderate. In particular, injection site reactions were more frequent with gefurulimab (n = 13; 9.9%) than placebo (n = 4; 3.1%), usually first appearing within 3 weeks, but no one left the trial because of it.

At the same time, serious AEs affected 12 patients in the gefurulimab arm (9.2%) and 15 in the placebo arm (11.6%), but none in the gefurulimab arm were considered treatment related. Similarly, neither of the 2 deaths, 1 per group, was attributed to the study drug.

“gMG is a disease marked by unpredictability and variability, for which early intervention and reliable disease control are critical treatment goals,” Kelly Gwathmey, MD, associate professor at Columbia University and PREVAIL trial principal investigator, said in a news release.1 “In the PREVAIL Phase III trial, gefurulimab achieved both, delivering rapid and sustained functional improvements with a once-weekly subcutaneous self-administered injection. With this approval, patients in the US gain a targeted treatment option that empowers greater autonomy with the established efficacy of C5 complement inhibition.”

The investigators acknowledged, however, that 6 months of randomized data are insufficient to establish gefurulimab’s long-term safety and efficacy, highlighting the ongoing open-label extension as a means of addressing these gaps.2

References

  1. Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients. News release. AstraZeneca. November 16, 2026. Accessed November 16, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/klygefa-gefurulimab-approved-in-the-US.html
  2. McNulty R. Weekly gefurulimab improves daily function in generalized MG. AJMC. October 30, 2026. Accessed November 16, 2026. https://www.ajmc.com/view/weekly-gefurulimab-improves-daily-function-in-generalized-mg

Related to this article